Payment overview · 2025
General Payments
$365.69
13 reported records · 9 companies
Healthcare provider profile · identity verified
Rachel E Soles, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · TRAVERSE CITY, MI · NPI 1033480769
Verified facts
What the public records show
CMS Open Payments records show Rachel E Soles, FNP received $365.69 in general payments during 2025 across 13 reported records.
Braeburn Inc. accounted for 32.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Braeburn Inc. | Unresolved — no canonical attribution shown | $120.21 | 32.9% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $75.47 | 20.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.34 | 9.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $32.23 | 8.8% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $30.11 | 8.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.48 | 6.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.70 | 5.4% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $15.60 | 4.3% | 1 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $14.55 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $365.69 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $120.21 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $55.88 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $32.23 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $30.11 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 239 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 27 |
| Levothyroxine Sodium | Levothyroxine Sodium | 192 | 26 |
| Losartan Potassium | Losartan Potassium | 185 | 21 |
| Lisinopril | Lisinopril | 178 | 23 |
| Omeprazole | Omeprazole | 168 | 22 |
| Eliquis | Apixaban | 141 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 19 |
| Atorvastatin Calcium | Atorvastatin Calcium | 115 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 90 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 15 |
| Bupropion Xl | Bupropion Hcl | 82 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 77 | 12 |
| Trazodone Hcl | Trazodone Hcl | 74 | 11 |
| Meloxicam | Meloxicam | 71 | 14 |
| Furosemide | Furosemide | 68 | 12 |
| Metformin Er Osmotic | Metformin Hcl | 65 | suppressed |
| Spironolactone | Spironolactone | 65 | suppressed |
| Ramelteon | Ramelteon | 60 | suppressed |
| Famotidine | Famotidine | 51 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 50 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 49 | suppressed |
| Trulicity | Dulaglutide | 48 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 47 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 17 |
| Myrbetriq | Mirabegron | 43 | 12 |
| Bumetanide | Bumetanide | 42 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | suppressed |
| Jardiance | Empagliflozin | 42 | suppressed |
| Potassium Chloride | Potassium Chloride | 39 | suppressed |
| Metformin Hcl | Metformin Hcl | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Loperamide | Loperamide Hcl | 35 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 20 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 32 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Prednisone | Prednisone | 31 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 12 |
| Finasteride | Finasteride | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Carvedilol | Carvedilol | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Mirabegron Er | Mirabegron | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 20 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 17 |
| Cinacalcet Hcl | Cinacalcet Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Buprenorphine | Buprenorphine | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Hydroxyurea | Hydroxyurea | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Famciclovir | Famciclovir | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Azathioprine | Azathioprine | 12 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Pentasa | Mesalamine | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Topiramate Er | Topiramate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Dalfampridine Er | Dalfampridine | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $365.69 · 13 records | Braeburn Inc. | ARISTADA, BRIXADI, Cologuard Collection Kit, Dexcom G6 Transmitter, LYBALVI, MAVYRET, SPRAVATO, SUBLOCADE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VIVITROL, Zubsolv | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error